CClinicalTrials.gg
Status unknownNCT05375396Updated May 16, 2022

Microbial Colonization of Dairy Free Oral Probiotics

An interventional study of Streptococcus salivarius M18 lozenges and Streptococcus salivarius M18 dairy free lozenges in Microbial Colonization, sponsored by John Hale. Status unknown at 1 site in New Zealand. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-16.

Sponsored by John Hale · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the colonization efficacy of probiotic lozenges containing dairy and dairy free probiotic Streptococcus salivarius M18, in healthy adults

Read the detailed description

This is a double-blind, randomized controlled colonization pilot study with no cross over to evaluate the colonization efficacy of two different lozenges containing either dairy or dairy free probiotic bacteria Streptococcus salivarius M18.

Participants will be randomly assigned to one of the 2 groups consuming probiotic lozenge containing dairy free Streptococcus salivarius M18 or dairy based Streptococcus salivarius M18 over a seven day period. Saliva samples will be collected at predetermined time points pre and post intervention. Colonization efficacy will be determined by enumerating the probiotic in the saliva samples using standard microbiological techniques.

02

Conditions studied

  • Microbial Colonization

Keywords

  • Streptococcus salivarius M18
  • dairy free
  • allergen free
  • probiotic
  • microbial colonization
  • oral probiotic
  • chewable tablet
03

In context

Communicable Diseases

4,452 studies on the registry are indexed under Communicable Diseases; 521 are open to participants now.

This study's planned enrollment of 30 is below the median of 122 across 2,718 interventional studies indexed under Communicable Diseases.

Browse Communicable Diseases studies →

Lead sponsor

John Hale is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Male or Female 18y - 80y age

  1. In general good health 18 - 80 years of age.
  2. Practice good oral hygiene.

Exclusion criteria

Exclusion criteria:

  1. Have a history of autoimmune disease or are immunocompromised.
  2. Are on concurrent antibiotic therapy or regular antibiotic use within last 1 week
  3. History of allergy (e.g. dairy).
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Streptococcus salivarius M18 lozenges

    Streptococcus salivarius M18 lozenges containing dairy based Streptococcus salivarius M18

    Dietary Supplement: Streptococcus salivarius M18 lozenges

  • Active comparator
    Streptococcus salivarius M18 dairy free lozenges

    Streptococcus salivarius M18 lozenges containing dairy free Streptococcus salivarius M18

    Dietary Supplement: Streptococcus salivarius M18 dairy free lozenges

Interventions

  • Dietary supplementStreptococcus salivarius M18 lozenges

    In this study, a lozenge formulation containing dairy based S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.

  • Dietary supplementStreptococcus salivarius M18 dairy free lozenges

    In this study, a lozenge formulation containing dairy free S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.

06

What researchers measure

Primary outcomes

  1. Change in microbial colonization of S. salivarius M18 from Day 0 (baseline) to 1 hour

    Study will determine the change in microbial colonization efficacy of dairy based Streptococcus salivarius M18 in a Lozenge format. The saliva Statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).

    Time frame: 1 hour post intervention

  2. Change in microbial colonization of S. salivarius M18 from Day 0 (baseline) to 8 hours

    Study will determine the change in microbial colonization efficacy of dairy based Streptococcus salivarius M18 in a Lozenge format. The saliva Statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).

    Time frame: 8 hour post intervention

  3. Change in microbial colonization of S. salivarius M18 from Day 0 (baseline) to 24 hours

    Study will determine the change in microbial colonization efficacy of dairy based Streptococcus salivarius M18 in a Lozenge format. The saliva Statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).

    Time frame: 24 hours post intervention

  4. Change in microbial colonization of S. salivarius M18 from Day 0 (baseline) to 48hours

    Study will determine the change in microbial colonization efficacy of dairy based Streptococcus salivarius M18 in a Lozenge format. The saliva Statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).

    Time frame: 48 hours post intervention

  5. Change in microbial colonization of dairy free S. salivarius M18 from Day 0 (baseline) to 1 hour

    Study will determine the change in microbial colonization efficacy of dairy based Streptococcus salivarius M18 in a Lozenge format. The saliva Statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).

    Time frame: 1 hour post intervention

  6. Change in microbial colonization of dairy free S. salivarius M18 from Day 0 (baseline) to 8 hour

    Study will determine the change in microbial colonization efficacy of dairy based Streptococcus salivarius M18 in a Lozenge format. The saliva Statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).

    Time frame: 8 hour post intervention

  7. Change in microbial colonization of dairy free S. salivarius M18 from Day 0 (baseline) to 24 hour

    Study will determine the change in microbial colonization efficacy of dairy based Streptococcus salivarius M18 in a Lozenge format. The saliva Statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).

    Time frame: 24 hour post intervention

  8. Change in microbial colonization of dairy free S. salivarius M18 from Day 0 (baseline) to 48 hour

    Study will determine the change in microbial colonization efficacy of dairy based Streptococcus salivarius M18 in a Lozenge format. The saliva Statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to one hour after later across two different formulations with the level of significance of p≤0.05.Overall colonization based on percentage of population colonized for different interventions will also be analyzed average and standard deviation functions using appropriate statistical analysis software (e.g. Microsoft Excel).

    Time frame: 48 hour post intervention

07

Study locations

1 of 1 sites recruiting
  • Blis Technologies Ltd
    Dunedin, Otago 9012, New Zealand
    Recruiting
08

References and documents

Publications

  • Di Pierro F, Zanvit A, Nobili P, Risso P, Fornaini C. Cariogram outcome after 90 days of oral treatment with Streptococcus salivarius M18 in children at high risk for dental caries: results of a randomized, controlled study. Clin Cosmet Investig Dent. 2015 Oct 3;7:107-13. doi: 10.2147/CCIDE.S93066. eCollection 2015. PubMed 26491371 ↗
  • Bardellini E, Amadori F, Gobbi E, Ferri A, Conti G, Majorana A. Does Streptococcus Salivarius Strain M18 Assumption Make Black Stains Disappear in Children? Oral Health Prev Dent. 2020 Apr 3;18(2):161-164. doi: 10.3290/j.ohpd.a43359. PubMed 32099975 ↗
  • Burton JP, Wescombe PA, Macklaim JM, Chai MH, Macdonald K, Hale JD, Tagg J, Reid G, Gloor GB, Cadieux PA. Persistence of the oral probiotic Streptococcus salivarius M18 is dose dependent and megaplasmid transfer can augment their bacteriocin production and adhesion characteristics. PLoS One. 2013 Jun 13;8(6):e65991. doi: 10.1371/journal.pone.0065991. Print 2013. PubMed 23785463 ↗
  • Burton JP, Drummond BK, Chilcott CN, Tagg JR, Thomson WM, Hale JDF, Wescombe PA. Influence of the probiotic Streptococcus salivarius strain M18 on indices of dental health in children: a randomized double-blind, placebo-controlled trial. J Med Microbiol. 2013 Jun;62(Pt 6):875-884. doi: 10.1099/jmm.0.056663-0. Epub 2013 Feb 28. PubMed 23449874 ↗

Individual participant data

Plan to share: Yes — Data and information included in the Protocol and Clinical Study Report will be shared to other researchers and/or in publications in due course.

Supporting information: Study protocol, Csr

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05375396
Lead sponsor
John Hale
Responsible party
John Hale (Chief Technology Officer, BLIS Technologies Limited) — Sponsor-investigator
First posted
May 16, 2022
Start date
Jun 1, 2022 (estimated)
Primary completion
Jul 1, 2022 (estimated)
Completion
Aug 1, 2022 (estimated)
Last update
May 16, 2022

Study contacts

John D Hale, PhD
Contact
john.hale@blis.co.nz
+6434740988
Rohit Jain, PhD
Contact
rohit.jain@blis.co.nz
+6434740988
John D D Hale, PhD
study director · Blis Technologies Ltd
Rohit Jain, PhD
principal investigator · Blis Technologies Ltd, Dunedin, New Zealand
John R Tagg, PhD
study director · Blis Technologies Ltd, Dunedin, New Zealand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion